Immune Checkpoint Inhibitors for Patients With Autoimmune Neurologic Disorders

This cohort study evaluates the safety and clinical outcomes of immune checkpoint inhibitor therapy among patients with neurologic autoimmune disorders, including multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome.

Read the full article here

Related Articles